<DOC>
	<DOCNO>NCT00825227</DOCNO>
	<brief_summary>Evaluate Safety Efficacy Armodafinil Treatment Patients With Fatigue Associated With Taxane Chemotherapy Alone Combination With Other Agents</brief_summary>
	<brief_title>Safety Efficacy Armodafinil Fatigue Associated With Taxanes Alone Combination With Other Agents</brief_title>
	<detailed_description>The primary objective study determine whether armodafinil treatment dose 150 mg/day effective placebo treatment reduce fatigue patient receive taxane chemotherapy alone combination agent compare change Screening cycle treatment cycle ( cycle 2 ) patient 's average daily rating bad fatigue severity past 24 hour . In addition , change percentage day severe fatigue mean Brief Fatigue Inventory score record .</detailed_description>
	<mesh_term>Fatigue</mesh_term>
	<mesh_term>Taxane</mesh_term>
	<mesh_term>Armodafinil</mesh_term>
	<mesh_term>Modafinil</mesh_term>
	<criteria>Key The patient cancer receiving , schedule receive , taxane chemotherapy ( paclitaxel , docetaxel , albuminbound paclitaxel ) , either alone combination agent . The patient experience average score 6 great daily bad fatigue severity assessment screening . The patient life expectancy least 6 month . The patient able use wrist actigraphy device provide write documentation screen period . The patient stable hemoglobin ( â‰¥10 g/dL ) throughout screen period . Women childbearing potential ( surgically sterile 2 year postmenopausal ) must use medically accept method contraception ( include abstinence ) must agree continue use method duration study 30 day participation study . Men surgically sterile capable produce offspring must practice abstinence use barrier method birth control , must agree continue use method duration study 30 day participation study . The patient adequate hepatic renal function . The patient meet propose diagnostic criterion cancerrelated fatigue include International Classifications Disease , Tenth Revision , Clinical Modification ( ICD10CM ) . If patient take chronic medication may affect fatigue ( e.g. , antidepressant , anxiolytic , opioid analgesic ) , dose stable least 4 week prior screen expect remain stable study . Key The patient untreated reversible medical condition may cause fatigue ( e.g. , metabolic disturbance , infection , endocrine abnormality ) . The patient receive concurrent stimulant medication ( e.g. , dextroamphetamine methylphenidate ) screen period doubleblind treatment period . The patient receive concurrent modafinil screen period doubleblind treatment period . The patient delay chemotherapy treatment screen period extend beyond 6 week . The patient know central nervous system ( CNS ) involvement metastatic cancer . The patient receive concurrent radiation therapy ( except palliative radiation ) treatment another investigational agent . The patient serious , uncontrolled , nonmalignant medical psychiatric disorder could impair conduct study safety patient . The patient pregnant lactating . The patient know HIV positivity . The patient nausea vomit gastrointestinal disorder severe enough interfere study drug absorption opinion investigator . The patient uncontrolled pain . The patient know hypersensitivity study medication ingredient study medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Fatigue</keyword>
	<keyword>Taxanes</keyword>
</DOC>